Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Codexis, Inc. (CDXS : NSDQ)

• Company Description    Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis? proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. Number of Employees: 188

• Price / Volume Information    Yesterday's Closing Price: $1.69 Daily Weekly Monthly 20 Day Moving Average: 867,616 shares Shares Outstanding: 90.27 (millions) Market Capitalization: $152.55 (millions) Beta: 2.57 52 Week High: $6.08 52 Week Low: $1.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -34.75% -36.46% 12 Week -43.85% -46.18% Year To Date -64.57% -69.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 200 PENOBSCOT DRIVE - REDWOOD CITY,CA 94063 USA ph: 650-421-8100 fax: 650-421-8102 ir@codexis.com http://www.codexis.com

• General Corporate Information    Officers Stephen Dilly - President; and Chief Executive Officer;Chairman of Georgia Erbez - Chief Financial Officer Raymond De Vre - Director Byron L. Dorgan - Director Esther Martinborough - Director Peer Information Codexis, Inc. (CORR.) Codexis, Inc. (RSPI) Codexis, Inc. (CGXP) Codexis, Inc. (BGEN) Codexis, Inc. (GTBP) Codexis, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 192005106 SIC: 2860 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 90.27 Most Recent Split Date: (:1) Beta: 2.57 Market Capitalization: $152.55 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.67 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.96 Price/Cash Flow: - Price / Sales: 2.88 EPS Growth vs. Year Ago Period: 24.14% vs. Previous Quarter: -37.50% Sales Growth vs. Year Ago Period: -32.98% vs. Previous Quarter: -43.89% ROE 09/30/25 - -121.39 06/30/25 - -105.83 03/31/25 - -118.47 ROA 09/30/25 - -47.36 06/30/25 - -46.06 03/31/25 - -53.37 Current Ratio 09/30/25 - 4.12 06/30/25 - 5.82 03/31/25 - 3.72 Quick Ratio 09/30/25 - 4.02 06/30/25 - 5.70 03/31/25 - 3.64 Operating Margin 09/30/25 - -120.82 06/30/25 - -113.67 03/31/25 - -149.47 Net Margin 09/30/25 - -120.82 06/30/25 - -113.67 03/31/25 - -149.47 Pre-Tax Margin 09/30/25 - -120.75 06/30/25 - -113.61 03/31/25 - -149.40 Book Value 09/30/25 - 0.43 06/30/25 - 0.67 03/31/25 - 0.60 Inventory Turnover 09/30/25 - 5.87 06/30/25 - 6.71 03/31/25 - 7.16 Debt-to-Equity 09/30/25 - 1.03 06/30/25 - 0.71 03/31/25 - 0.59 Debt-to-Capital 09/30/25 - 50.76 06/30/25 - 41.44 03/31/25 - 37.03

Powered by Zacks Investment Research ©